Orphan Drugs Would Get User Fee Waivers With Greater Ease Under House Bill

Provisions in the House version of the FDA user fee bill would raise the cut-off for an orphan drug to qualify for a user fee waiver from firms with less than $10 million in annual revenue to firms with less then $100 million